

Stella Maris Ranuncolo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1329408/publications.pdf>

Version: 2024-02-01

26
papers

1,495
citations

516710

16
h-index

610901

24
g-index

27
all docs

27
docs citations

27
times ranked

2177
citing authors

#	ARTICLE	IF	CITATIONS
1	Apoptotic regulator BCL-2 blockade as a potential therapy in classical Hodgkin Lymphoma. <i>Life Sciences</i> , 2021, 268, 118979.	4.3	4
2	Lymphotropic Viruses EBV, KSHV and HTLV in Latin America: Epidemiology and Associated Malignancies. A Literature-Based Study by the RIAL-CYTED. <i>Cancers</i> , 2020, 12, 2166.	3.7	16
3	Alternative and canonical NF- κ B pathways DNA-binding hierarchies networks define Hodgkin lymphoma and Non-Hodgkin diffuse large B Cell lymphoma respectively. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1437-1448.	2.5	15
4	Related F-box proteins control cell death in <i>Caenorhabditis elegans</i> and human lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 3943-3948.	7.1	57
5	Hodgkin lymphoma requires stabilized NIK and constitutive RelB expression for survival. <i>Blood</i> , 2012, 120, 3756-3763.	1.4	68
6	Evidence of the Involvement of O-GlcNAc-modified Human RNA Polymerase II CTD in Transcription in Vitro and in Vivo. <i>Journal of Biological Chemistry</i> , 2012, 287, 23549-23561.	3.4	142
7	BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt. <i>Blood</i> , 2009, 114, 5315-5321.	1.4	53
8	BCL6 represses CHEK1 and suppresses DNA damage pathways in normal and malignant B-cells. <i>Blood Cells, Molecules, and Diseases</i> , 2008, 41, 95-99.	1.4	84
9	BCL6-mediated Attenuation of DNA Damage Sensing Triggers Growth Arrest and Senescence through a p53-dependent Pathway in a Cell Context-dependent Manner. <i>Journal of Biological Chemistry</i> , 2008, 283, 22565-22572.	3.4	38
10	BCL6 Regulates Tonic BCR Signaling in Diffuse Large B-Cell Lymphomas by Repressing the SYK Phosphatase, PTPROt. <i>Blood</i> , 2008, 112, 802-802.	1.4	0
11	BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. <i>Blood</i> , 2007, 110, 2067-2074.	1.4	117
12	Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. <i>Nature Immunology</i> , 2007, 8, 705-714.	14.5	231
13	A "Survival of the Fittest" Mechanism for Weeding Out Potentially Lymphomagenic B-Cells during Germinal Center B-Cell Differentiation.. <i>Blood</i> , 2007, 110, 559-559.	1.4	0
14	Inhibition of Tumor Progression and Paraneoplastic Syndrome Development in a Murine Lung Adenocarcinoma by Medroxyprogesterone Acetate and Indomethacin. <i>Cancer Investigation</i> , 2006, 24, 126-131.	1.3	23
15	A Critical BCL6-Related Feedback Loop Explains the Unusual Biological Features of Germinal Center B-Cells and Their Malignant Transformation into B-Cell Lymphomas.. <i>Blood</i> , 2006, 108, 224-224.	1.4	2
16	BCL6 Programs Lymphoma Cells for Survival and Differentiation through Distinct Biochemical Mechanisms, Both of Which Can Be Therapeutically Targeted.. <i>Blood</i> , 2006, 108, 225-225.	1.4	1
17	The BCL6 Oncoprotein Forms Distinct Transcriptional Repression Complexes on Cohorts of Target Genes Involved in Specific Cellular Functions.. <i>Blood</i> , 2005, 106, 2615-2615.	1.4	0
18	Prognostic Value of Mdm2, p53 and p16 in Patients with Astrocytomas. <i>Journal of Neuro-Oncology</i> , 2004, 68, 113-121.	2.9	29

#	ARTICLE	IF	CITATIONS
19	EGF-R and PDGF-R, but not bcl-2, overexpression predict overall survival in patients with low-grade astrocytomas. <i>Journal of Surgical Oncology</i> , 2004, 86, 34-40.	1.7	69
20	Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. <i>Nature Medicine</i> , 2004, 10, 1329-1335.	30.7	272
21	Specific Peptide Disruption of the Bcl-6 Repression Complex Reveals Its Transcriptional Mechanism of Action in Normal and Malignant B-Cells and Is a Novel Therapeutic Approach for Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2004, 104, 5-5.	1.4	3
22	Plasma MMPâ€9 (92 kDaâ€MMP) activity is useful in the followâ€up and in the assessment of prognosis in breast cancer patients. <i>International Journal of Cancer</i> , 2003, 106, 745-751.	5.1	116
23	CD44 expression in human gliomas. <i>Journal of Surgical Oncology</i> , 2002, 79, 30-36.	1.7	57
24	Circulating 92-kilodalton matrix metalloproteinase (MMP-9) activity is enhanced in the euglobulin plasma fraction of head and neck squamous cell carcinoma. <i>Cancer</i> , 2002, 94, 1483-1491.	4.1	35
25	Expression of CD44s and CD44 splice variants in human melanoma. <i>Oncology Reports</i> , 2002, 9, 51-6.	2.6	15
26	Plasma metalloproteinase activity is enhanced in the euglobulin fraction of breast and lung cancer patients. <i>International Journal of Cancer</i> , 2000, 89, 389-394.	5.1	47